Table 2.
Comparison of key characteristics of the 5 cancer-related identities
| Someone who has had cancer n = 830 (%) |
Patient n = 627 (%) |
Cancer conqueror n = 145 (%) |
Cancer survivor n = 139 (%) |
Victim n = 31 (%) |
||
|---|---|---|---|---|---|---|
| Age at survey (years) | p = .0008 | |||||
| ≤ 60 | 13.0 | 8.6 | 6.9 | 5.8 | 6.5 | |
| > 60 to ≤ 70 | 35.1 | 28.7 | 32.4 | 30.2 | 25.8 | |
| > 70 | 51.9 | 62.7 | 60.7 | 64.0 | 67.7 | |
| Partnership | p = .44 | |||||
| Yes | 85.8 | 86.4 | 91.3 | 88.2 | 90.3 | |
| No | 14.2 | 13.6 | 8.7 | 11.8 | 9.7 | |
| Children | p = .22 | |||||
| ≥ 1 | 80.7 | 79.7 | 78.0 | 88.4 | 84.0 | |
| 0 | 19.3 | 20.3 | 22.0 | 11.6 | 16.0 | |
| Age at surgery (years) | p < .0001 | |||||
| ≤ 55 | 11.5 | 8.8 | 8.3 | 2.2 | 6.5 | |
| > 55 to ≤ 65 | 37.7 | 27.6 | 32.4 | 36.7 | 25.8 | |
| > 65 | 50.8 | 63.6 | 59.3 | 61.1 | 67.7 | |
| Time since surgery (years) | p = .12 | |||||
| 1–2 | 29.8 | 27.9 | 22.1 | 18.7 | 35.5 | |
| 3–5 | 31.5 | 33.0 | 34.5 | 31.7 | 25.8 | |
| > 5 | 38.7 | 39.1 | 43.4 | 49.6 | 38.7 | |
| Second primary cancer | p = .93 | |||||
| Yes | 8.7 | 7.5 | 7.6 | 7.9 | 6.5 | |
| No | 91.3 | 92.5 | 92.4 | 92.1 | 93.5 | |
| Family history of PCa | p = .43 | |||||
| Yes | 28.4 | 27.6 | 29.7 | 28.1 | 12.9 | |
| No | 71.6 | 72.4 | 70.3 | 71.9 | 87.1 | |
| Family history of cancer (other than PCa) | p = .056 | |||||
| Yes | 46.8 | 42.4 | 46.2 | 39.6 | 64.5 | |
| No | 53.2 | 57.6 | 53.8 | 60.4 | 35.5 | |
| PSA Lever at diagnosis (ng/ml) | p = .006 | |||||
| ≤ 4 | 11.9 | 8.3 | 8.3 | 9.4 | 6.5 | |
| > 4 ≤ 10 | 65.3 | 61.6 | 56.5 | 57.5 | 64.5 | |
| > 10 | 22.8 | 30.1 | 35.2 | 33.1 | 29.0 | |
| Gleason grade group (1–5) | p < .0001 | |||||
| ISUP 1 | 17.7 | 11.7 | 14.5 | 10.1 | 0.0 | |
| ISUP 2 | 48.7 | 42.3 | 40.0 | 40.3 | 29.0 | |
| ISUP 3 | 22.6 | 27.8 | 29.0 | 21.6 | 45.2 | |
| ISUP 4 | 4.1 | 6.1 | 9.7 | 8.6 | 6.5 | |
| ISUP 5 | 6.9 | 12.1 | 6.9 | 19.4 | 19.4 | |
| Organ-confined stage at RP | p < .0001 | |||||
| Yes | 65.7 | 54.6 | 57.9 | 41.0 | 41.9 | |
| No | 34.3 | 45.5 | 42.1 | 59.0 | 58.1 | |
| Biochemical recurrence | p < .0001 | |||||
| Yes (progress not ongoing) | 9.0 | 15.5 | 15.4 | 10.1 | 20.7 | |
| Yes (progress ongoing) | 6.0 | 14.9 | 7.0 | 18.1 | 17.2 | |
| No | 85.0 | 69.8 | 77.6 | 71.7 | 62.1 | |
| Ongoing treatment at survey | p < .0001 | |||||
| Yes | 3.1 | 13.6 | 2.1 | 13.7 | 19.4 | |
| No | 96.9 | 86.4 | 97.9 | 86.3 | 80.7 | |
| Adjuvant therapy | p < .0001 | |||||
| Radiotherapy | 6.6 | 9.7 | 12.4 | 18.0 | 19.4 | |
| Androgen deprivation therapy | 2.2 | 5.3 | 4.1 | 5.8 | 3.2 | |
| No | 91.2 | 85.0 | 83.5 | 76.2 | 77.4 | |
| RCS Charlson Score (at surgery) | p = .015 | |||||
| 0 | 88.0 | 83.6 | 82.1 | 79.8 | 77.4 | |
| 1 | 10.1 | 12.0 | 11.0 | 17.3 | 16.2 | |
| ≥ 2 | 1.9 | 4.4 | 6.9 | 2.9 | 6.4 | |
| Urinary continence | p < .0001 | |||||
| Yes | 77.0 | 77.5 | 78.2 | 62.0 | 40.0 | |
| No (continent prior to surgery) | 23.0 | 22.5 | 21.8 | 38.0 | 60.0 | |
| Sexual activity independent of partner | p = .0002 | |||||
| Yes | 76.6 | 65.7 | 64.1 | 61.5 | 59.3 | |
| No (sexual activity prior to surgery) | 17.1 | 24.1 | 27.5 | 25.7 | 26.0 | |
| No (no sexual activity prior to surgery) | 6.3 | 10.2 | 8.4 | 12.9 | 14.8 | |
| Masturbation | p < .0001 | |||||
| Yes | 63.6 | 49.4 | 50.4 | 41.7 | 32.1 | |
| No (masturbation prior to surgery) | 6.4 | 7.3 | 8.5 | 5.8 | 7.1 | |
| No (no masturbation prior to surgery) | 12.4 | 16.6 | 16.3 | 22.5 | 25.0 | |
| No | 17.6 | 26.7 | 24.8 | 30.0 | 35.7 | |
| Partnered sexual activity | p = .042 | |||||
| Yes | 46.5 | 40.5 | 38.9 | 34.3 | 30.8 | |
| No (partnered sexual activity prior to surgery) | 33.5 | 34.6 | 36.5 | 32.4 | 42.3 | |
| No (no partnered sexual activity prior) | 20.0 | 25.0 | 24.6 | 33.3 | 26.9 | |
| PHQ-2 (depression screening) | p < .0001 | |||||
| Positive screening (≥ 3) | 6.4 | 8.9 | 5.6 | 12.7 | 27.6 | |
| Negative screening (< 3) | 93.6 | 91.1 | 94.4 | 87.3 | 72.4 | |
| GAD-2 (anxiety disorder screening) | p < .0001 | |||||
| Positive screening (≥ 3) | 6.1 | 7.3 | 4.9 | 15.3 | 29.0 | |
| Negative screening (< 3) | 93.9 | 92.7 | 95.1 | 84.7 | 71.0 | |
| Quality of life QLQ-C30 | p < .0001 | MW: 74.7 SD:17.7 | MW: 72.7 SD:18.9 | MW: 81.0 SD:15.4 | MW: 69.1 SD:20.3 | MW: 54.3 SD:18.6 |
| Distress (QSC-R10) FBK10 | p < .0001 | |||||
| High (> 14) | 19.4 | 26.4 | 14.7 | 35.8 | 58.1 | |
| Low (≤ 14) | 80.6 | 73.6 | 85.3 | 64.2 | 41.9 | |
| Psychosocial counseling desired* | p = .018 | |||||
| Yes | 21.6 | 26.3 | 17.5 | 29.9 | 34.5 | |
| No | 78.4 | 73.7 | 82.5 | 70.1 | 65.5 | |
| Perceived severity of disease | p < .0001 | |||||
| High | 42.0 | 42.9 | 42.7 | 61.5 | 90.3 | |
| Low | 58.0 | 57.1 | 57.3 | 38.5 | 9.7 | |
| Benefit finding | p < .0001 | |||||
| High | 48.1 | 44.7 | 65.3 | 68.9 | 51.6 | |
| Low | 51.9 | 55.3 | 34.7 | 31.1 | 48.4 | |
PCa, prostate cancer; PSA, prostate specific antigen; ISUP, The International Society of Urological Pathology; RP, radical prostatectomy; RCS, Royal College of Surgeons; PHQ, patient health questionnaire; GAD, general anxiety disorder; QSC-R10, Questionnaire on Stress in Cancer Patients; EORTC QLQ, European Organization for Research and Treatment of Cancer Quality of Life Questionnaire